Mary Beattie, MD, MAS

Mary beattie, md, mas

bookmark on deepenrich
  • Timeline

  • About me

    Global Director, Alliance and Asset Management at Genentech

  • Education

    • University of california, san francisco - school of medicine

      -
      Mas clinical research
    • Duke university

      -
      Bs chemistry

      Activities and Societies: Chi Omega, Wannamaker Freshman Dormitory, Phi Eta Sigma Honor Society, Dean's List, Summer Study Abroad in the Soviet Union, Graduation with Distinction in Chemistry with Senior Thesis

    • The ohio state university college of medicine

      -
      Md medicine

      Activities and Societies: Landacre Research Society Sarnoff Research Scholarship

  • Experience

    • Ucsf health

      Jan 1996 - Jul 2011
      Associate professor of medicine

      Breast Cancer Research, Medical Student and Resident Education, Managing Women's Health Programs

    • University of california, san francisco

      Apr 2009 - Apr 2021

      Mary advanced to full professor at UCSF in 2011. Her clinical and academic research interests were in Hereditary Breast and Ovarian Cancer. She taught clinical epidemiology and research methods to hundreds of UCSF students, and mentored many students, residents, fellows, and junior faculty throughout the university. Mary managed and directed several innovative UCSF programs, including clinical research programs relating to cancer risk as well as student research programs that emphasized multi-disciplinary and translational legacy projects. Show less

      • Volunteer Clinical Professor

        Apr 2012 - Apr 2021
      • Professor of Medicine

        Jul 2011 - Apr 2012
      • Director of Clinical Research, UCSF Cancer Risk Program

        Jul 2006 - Apr 2012
      • Director, Resource Allocation Program for Trainees

        Oct 2011 - Mar 2012
      • Associate Director, UCSF Office of Student Research

        Apr 2009 - Mar 2012
    • Genentech

      Apr 2012 - now

      Global Director, Alliance and Asset Management, Pharma PartneringGenentech, a member of the Roche Group Mary served as senior medical director for Precision Medicine in US Medical Affairs, BioOncology. She led the MyPathway trial, a phase II multi-basket study of 8 molecules in all solid tumors. She also developed a Precision Medicine team that brought in multi-disciplinary functions to assist with strategic planning, communications, and data generation for Precision Medicine. Mary led the Perjeta Medical Team for US Medical Affairs, where she worked with multi-disciplinary functions, and represented the US on global teams, as well as development and life-cycle teams. She also worked on the MyPathway Trial and the SystHERs patient registry study. Mary worked in US Medical Affairs (USMA) to lead and co-lead several innovative research studies and projects in breast oncology, gynecologic oncology, and precision medicine. These include: the SystHERs Registry (HER2+ metastatic breast cancer), the My Pathway Trial (multi-basket precision medicine trial), the Avastin USMA Women's Health team, and the Perjeta USMA Women's Health team. Mary worked with multidisciplinary cross-functional teams to rigorously study the science of patient care in real-world settings. She started the SystHERs registry for over 1000 patients with HER2+ metastatic breast cancer

      • Global Director, Alliance and Asset Management

        Apr 2021 - now
      • Global Group Medical Director

        May 2019 - Apr 2021
      • Principal Medical Director

        Sept 2018 - Apr 2019
      • Senior Medical Director, Precision Medicine

        Sept 2016 - Sept 2018
      • Senior Medical Director

        Oct 2015 - Sept 2016
      • Medical Director, Women's Health BioOncology

        Apr 2013 - Oct 2015
      • Medical Director, Patient Registries

        Apr 2012 - Apr 2013
    • Roche/genentech

      May 2019 - Apr 2021
      Global group medical director, personalized health care
  • Licenses & Certifications